Sangboonruang Sirikwan, Semakul Natthawat, Suriyaprom Sureeporn, Kitidee Kuntida, Khantipongse Jiaranai, Intorasoot Sorasak, Tharinjaroen Chayada Sitthidet, Wattananandkul Usanee, Butr-Indr Bordin, Phunpae Ponrut, Tragoolpua Khajornsak
Division of Clinical Microbiology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.
Infectious Diseases Research Unit (IDRU), Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.
Nanomaterials (Basel). 2023 Jan 8;13(2):269. doi: 10.3390/nano13020269.
Tuberculosis (TB) therapy requires long-course multidrug regimens leading to the emergence of drug-resistant TB and increased public health burden worldwide. As the treatment strategy is more challenging, seeking a potent non-antibiotic agent has been raised. Propolis serve as a natural source of bioactive molecules. It has been evidenced to eliminate various microbial pathogens including (Mtb). In this study, we fabricated the niosome-based drug delivery platform for ethanolic extract of propolis (EEP) using thin film hydration method with Ag85A aptamer surface modification (Apt-PEGNio/EEP) to target Mtb. Physicochemical characterization of PEGNio/EEP indicated approximately -20 mV of zeta potential, 180 nm of spherical nanoparticles, 80% of entrapment efficiency, and the sustained release profile. The Apt-PEGNio/EEP and PEGNio/EEP showed no difference in these characteristics. The chemical composition in the nanostructure was confirmed by Fourier transform infrared spectrometry. Apt-PEGNio/EEP showed specific binding to expressing Ag85 membrane-bound protein by confocal laser scanning microscope. It strongly inhibited Mtb in vitro and exhibited non-toxicity on alveolar macrophages. These findings indicate that the Apt-PEGNio/EEP acts as an antimycobacterial nanoparticle and might be a promising innovative targeted treatment. Further application of this smart nano-delivery system will lead to effective TB management.
结核病(TB)治疗需要长期的多药联合治疗方案,这导致了耐多药结核病的出现,并增加了全球公共卫生负担。由于治疗策略更具挑战性,人们开始寻求一种有效的非抗生素药物。蜂胶是生物活性分子的天然来源。已有证据表明它能消除包括结核分枝杆菌(Mtb)在内的多种微生物病原体。在本研究中,我们采用薄膜水化法并进行Ag85A适配体表面修饰(Apt-PEGNio/EEP),制备了基于脂质体的蜂胶乙醇提取物(EEP)药物递送平台,以靶向结核分枝杆菌。PEGNio/EEP的物理化学特性表明其zeta电位约为-20 mV,球形纳米颗粒直径为180 nm,包封率为80%,且具有缓释特性。Apt-PEGNio/EEP和PEGNio/EEP在这些特性上没有差异。通过傅里叶变换红外光谱法确认了纳米结构中的化学成分。通过共聚焦激光扫描显微镜观察,Apt-PEGNio/EEP对表达Ag85膜结合蛋白的细胞显示出特异性结合。它在体外能强烈抑制结核分枝杆菌,并且对肺泡巨噬细胞无毒。这些发现表明Apt-PEGNio/EEP可作为一种抗分枝杆菌纳米颗粒,可能是一种有前景的创新靶向治疗方法。这种智能纳米递送系统的进一步应用将有助于实现有效的结核病管理。